Parkinson’s Foundation and Tag.bio Partner to Accelerate Research and Drive Insights into Parkinson’s Disease
NEW YORK & SAN FRANCISCO (November 29, 2022) — The Parkinson’s Foundation, one of the world’s leading organizations making life better for people with Parkinson’s disease (PD) and Tag.bio, the leader in data mesh (a self-service, no-code/low-code, decentralized, domain-driven software platform), today announced a partnership that will help accelerate research into the causes and treatment of PD.
“We are thrilled to partner with the Parkinson’s Foundation, a global leader in improving life for those living with Parkinson’s disease,” said Tom Covington, CEO of Tag.bio. “With this partnership, for the first time, researchers across organizations will be able to investigate harmonized, clinical and genomics data products using the most advanced data mesh framework, to help advance research into the causes and treatment of Parkinson’s disease”.
The partnership with the Parkinson’s Foundation will enable researchers across organizations to securely analyze and share anonymized data combining clinical and genomics data sets with millions of variants and thousands of clinical parameters. Data Products interrogated via Apps and developer environments within the platform provide detailed insights on disease progression and map clinically relevant PD-related genes. The goal is to improve care for PD by accelerating and supporting research to advance improved treatments and personalized medicine.
“By providing the research community with tools and a library of data, we hope to make strides in advancing Parkinson’s research, spark discoveries in treatment and improve the overall care of people living with the disease,” said Parkinson’s Foundation Chief Scientific Officer James Beck, PhD.
The Parkinson’s Foundation will support the research community by linking multiple deidentified datasets from PD GENEration: Mapping the Future of Parkinson’s Disease, a national initiative that provides genetic testing and counseling for seven PD-related genes to individuals with a confirmed PD diagnosis at no cost. The study aims to help people with PD and their physicians identify whether they qualify for enrollment in certain clinical trials based on their results. The newly established partnership will support the study’s goal of improving PD care by accelerating and supporting research to advance improved treatments and personalized medicine.
Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is estimated that one million Americans and 10 million individuals worldwide are affected by this disease. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the U.S. alone.
About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $400 million in Parkinson’s research and clinical care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or call (800) 4PD-INFO (473-4636).
About Parkinson’s Disease
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the U.S. alone.
Tag.bio, enables organizations to securely derive insights using data-as-products in a data mesh architecture. Customers use Tag.bio’s data science platform to discover, share, and unite diverse siloed data sets and execute workloads using no-code/low-code data mesh framework. The data science platform (available in AWS and Azure Marketplaces) combines data sets, smart APIs, statistical and machine learning algorithms into data products (application layer) for users to discover insights via apps. Learn more at https://tag.bio.